Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 dose escalation clinical trial of CRB 701 in advanced solid tumors

Next Previous
Trial Profile

A Phase 1 dose escalation clinical trial of CRB 701 in advanced solid tumors

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 21 Feb 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CRB 701 (Primary)
  • Indications Cervical cancer; Colorectal cancer; Head and neck cancer; Skin disorders; Solid tumours; Squamous cell cancer; Triple negative breast cancer; Urogenital cancer
  • Focus Adverse reactions; First in man
  • Acronyms Western study
  • Sponsors CSPC Pharmaceutical Group

Most Recent Events

  • 14 Feb 2025 According to a Corbus Pharmaceuticals media release,,The Western study opened for enrollment in April 2024 and enrollment for dose escalation was completed in October 2024.
  • 14 Feb 2025 According to a Corbus Pharmaceuticals media release, data from the study were presented at the 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU).
  • 14 Feb 2025 Results (December 2024 data cut, n=38) presented in the Corbus Pharmaceuticals Media Release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top